کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
11019130 1718898 2019 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی ژنتیک
پیش نمایش صفحه اول مقاله
Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis
چکیده انگلیسی
Alemtuzumab (a drug highly active in multiple sclerosis) is a humanized monoclonal antibody targeting the surface molecule CD52. It causes a rapid depletion of innate and adaptive immune cells with a peak during the first month after infusion. Infection rates in alemtuzumab-treated patients with multiple sclerosis in clinical trials were higher in than in interferon beta-treated patients. Cytomegalovirus (CMV) primary infections and reactivations have been reported in this setting of patients. We describe the case of a patient that developed both viral (CMV) and bacterial pneumonia one month after alemtuzumab infusion for multiple sclerosis. Physicians dealing with this drug should be aware of this serious but treatable complication.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Multiple Sclerosis and Related Disorders - Volume 27, January 2019, Pages 44-45
نویسندگان
, , , , , , , , ,